TNYA — Tenaya Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $294.99m
- $223.32m
- 24
- 18
- 86
- 37
Annual income statement for Tenaya Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 38.9 | 72.8 | 126 | 131 | 116 |
| Operating Profit | -38.9 | -72.8 | -126 | -131 | -116 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -38.4 | -72.7 | -124 | -124 | -111 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -38.4 | -72.7 | -124 | -124 | -111 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -38.4 | -72.7 | -124 | -124 | -111 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -38.4 | -72.7 | -124 | -124 | -111 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.976 | -4.1 | -2.76 | -1.68 | -1.31 |
| Dividends per Share |